BioNTech Posts Quarterly Profit but Trims Mainz Staff as Founder Transition Raises Questions
Published on 11/21/2026 at 20:10 | Editorial boerse-global.deBioNTech returned to profit in the third quarter of 2026, reporting net income of €184.5 million on revenue of €1.29 billion — a swing back into the black that contrasts sharply with the company's nine-month tally. Across the first three quarters of 2026, the Mainz-based biotech booked a net loss of €1.17 billion on revenue of €1.51 billion, a shortfall management attributes chiefly to the anticipated drop in demand for COVID-19 vaccines.
Guidance Raised Despite Revenue Decline
Alongside the quarterly figures released on 3 November, BioNTech lifted the midpoint of its full-year 2026 revenue forecast. The company now expects sales of between €1.7 billion and €1.9 billion for the year as a whole.
The improved outlook comes as BioNTech moves to reshape its cost base. According to Business Insider, roughly 40 positions are set to be cut at the company's main site in Mainz — reductions that sit on top of the approximately 1,800 jobs already earmarked for elimination at other locations. The Mainz plans only became public today.
A $205 Million Ticket to a Faster FDA Review
Separately, BioNTech has agreed to acquire a priority review voucher from Scholar Rock for $205 million in cash. The company intends to deploy the voucher in a future application for a cancer drug drawn from its advanced development pipeline. Completion of the deal is subject to customary conditions, including antitrust clearance under the HSR process.
Should investors sell immediately? Or is it worth buying BioNTech?
BioNTech pushed back on a Business Insider account suggesting the voucher had been tied to a specific active substance candidate. The Handelsblatt, for its part, grouped the voucher purchase alongside the German site closures and the company's broader savings programme.
Roche and Genentech Take Over the R&D Tab
In a further development disclosed with the quarterly results, BioNTech confirmed it has exercised an option within its collaboration with Roche and Genentech. From 1 January 2027, the partners will in principle assume the future research and development costs of the joint programme. BioNTech retains a stake in potential licensing revenue should the programme advance successfully to development and commercialisation.
Questions Swirl Around the Founders' Next Move
Business Insider also flagged unresolved issues surrounding the planned departure of BioNTech founders U?ur ?ahin and Özlem Türeci to Arife, a new venture. Among the open points: which employees will make the move to Arife, and which patents could be transferred to the new company.
BioNTech at a turning point? This analysis reveals what investors need to know now.
J.P. Morgan Nudges Its Target Higher
On Thursday, J.P. Morgan raised its price target on the stock from $92 to $93 while keeping its rating at "Neutral."
Ad
BioNTech Stock: New Analysis - 21 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
